ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bracco and GE Healthcare side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BraccoGE Healthcare
studies on the registry66183
open to participants now522
phase 3 studies under way12
reach primary completion within a year011
programswith a study of their own in two years33

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBraccoGE Healthcare
Phase 100%00%
Phase 2

Bracco: 2 of its 3 programs at phase 2

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2
67%

GE Healthcare: 1 of its 3 programs at phase 2

  1. GE-287phase 2
33%
Phase 300%

GE Healthcare: 2 of its 3 programs at phase 3

  1. Gallium-68phase 3
  2. Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLphase 3
67%
Approved, new studies

Bracco: 1 of its 3 programs at approved, new studies

  1. fluciclovine F-18approved, new study
33%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bracco0 readouts · 0 phase 3············
GE Healthcare1 readouts · 0 phase 3···

GE Healthcare, Feb ’27: 1 program whose next study reaches primary completion

  1. GE-287phase 2 · Feb 25 · NCT07873463
········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bracco

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

GE Healthcare

New programs 1

  • GE-287phase 2 · first study · Sep 21 · Cognitive Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionBraccoGE Healthcare
Colorectal Neoplasmsboth · compare here

Bracco in Colorectal Neoplasms: 2 programs

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2

Their studies: Bracco’s studies of Colorectal Neoplasms in search

GE Healthcare in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: GE Healthcare’s studies of Colorectal Neoplasms in search

Prostatic Neoplasmsboth · compare here

Bracco in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 2
  2. fluciclovine F-18approved, new study

Their studies: Bracco’s studies of Prostatic Neoplasms in search

GE Healthcare in Prostatic Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: GE Healthcare’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

Bracco in Breast Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Breast Neoplasms in search

GE Healthcare in Breast Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: GE Healthcare’s studies of Breast Neoplasms in search

Carcinoma, Renal Cellboth · compare here

Bracco in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Carcinoma, Renal Cell in search

GE Healthcare in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: GE Healthcare’s studies of Carcinoma, Renal Cell in search

Urinary Bladder Neoplasmsboth · compare here

Bracco in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Urinary Bladder Neoplasms in search

GE Healthcare in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: GE Healthcare’s studies of Urinary Bladder Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bracco 2 of 3 · GE Healthcare 1 of 3 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.